Is SS-31 safe?
Emerging ResearchSide effects, risks, and safety considerations based on available research.
Research status
SS-31 has some clinical data but research is still developing. Safety data exists but may come from small studies, short-term trials, or specific populations that may not reflect your situation.
Known concerns & side effects
- ⚠not FDA-approved — failed to meet primary endpoint in pivotal Barth syndrome trial despite showing biological activity
- ⚠injection site reactions reported in clinical trials
- ⚠long-term safety data in healthy individuals is very limited
- ⚠most aging-related evidence comes from animal models, not humans
- ⚠sourcing from research chemical suppliers carries purity and contamination risks
Use caution with
Relevant safety research
Effects of elamipretide on left ventricular function in patients with heart failure with reduced ejection fraction
Finding: Single infusion of elamipretide showed dose-dependent improvements in left ventricular end-systolic volume, suggesting improved cardiac function.
Limitation: Single-dose study. Longer-term efficacy and safety not established. Heart failure population, not healthy aging.
See all 3 studies on the full SS-31 profile.
Frequently asked questions
How is SS-31 different from regular antioxidants?
Traditional antioxidants like vitamin C or E work by neutralizing free radicals after they are produced. SS-31 takes a fundamentally different approach — it stabilizes the mitochondrial membrane to prevent excessive ROS production in the first place. This upstream mechanism is why researchers consider it more promising than conventional antioxidant supplementation for mitochondrial dysfunction.
Why did SS-31 fail its Barth syndrome trial?
The pivotal phase III trial did not meet its primary endpoint (6-minute walk distance improvement) despite showing improvements in secondary endpoints like cardiac stroke volume and biomarkers. This is common in rare disease trials with small sample sizes and variable disease severity. The biological activity was real, but the trial design may not have captured it in the primary outcome.
Is SS-31 related to MOTS-c?
Both target mitochondria but through completely different mechanisms. MOTS-c is a naturally occurring mitochondrial-derived peptide that activates AMPK signaling. SS-31 is a synthetic peptide that directly stabilizes the inner mitochondrial membrane. They represent complementary approaches to mitochondrial health and are sometimes discussed together in longevity circles.
Full SS-31 Profile
Evidence, timeline, products & more
Take the Peptide Quiz
Get personalized recommendations
Last updated: 2026-04-26
Medical Disclaimer
The information on this site is for educational and informational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, or prevent any condition. Always consult with a qualified healthcare professional before starting any new supplement, peptide, or treatment protocol.